Treatment of throat infection with Unani medicine Habb-e-Khardal
- Conditions
- Chronic pharyngitis,
- Registration Number
- CTRI/2024/07/071434
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
This study is designed as a multi centric open trial in patients with **Warm-e-Halaq (Pharyngitis)****.**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be assessed clinically at every week. This includes subjective assessment of general well being and physical examination. The total duration of treatment will be 14days. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.
The treatment of *waram-e-halaq*has been described in Unani system of medicine. There are so many *Mufrad*(single) as well as *Murakkab* (Compound) Unani formulations mentioned inclassical texts which have been used in the treatment of *waram-e-halaq*by eminent Unani Physicians since ages and are known for theirefficacy and safety, but they need to be validated on scientific parameters inorder to generate data regarding their safety and efficacy.
*Habb-e-khardal* is an UnaniPharmacopoeial Formulation widely used by Unani physicians to relieve symptomsof*waram-e-halaq*(Pharyngitis).Therefore, the present clinical study has been planned to scientificallyvalidate the efficacy and safety of *Habb-e-khardal* in the treatment ofespecially in *waram-e-halaq*(Pharyngitis).
**Composition of *HABB -E -KHARDAL***
| | | | | |
| --- | --- | --- | --- | --- |
|**S. No.**
**Ingredients**
**Scientific Name**
**Quantity**
**Ratio proportion**
|1.
*Filfil Siyah*
*Piper nigrum* Linn
10g
1
|2.
*Khardal biryan*
*Brassica nigra*
10g
1
|3.
*Kundur*
*Boswellia**serrata* Roxb
60g
6
|4.
*Mur Makki*
*Commiphora myrrha* Engl.
60g
6
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 300
- Patients of either sex in the age group of 18-60 years.
- Patients having Sore throat Pharyngeal Inflammation along with any of these Cough Rhinorrhoea Hoarseness Oral ulcers Conjunctivitis.
- Age below 18 and more than 60.
- Patient with GERD.
- Patient having bacterial pharyngitis.
- Fever more than 100 F 5.
- Weak debilitating patients 6.
- Known cases of other clinically significant co-morbid conditions (severe hepatitis, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study.
- Patients with laboratory values outside the normal limits or those with values considered abnormal in the opinion of the investigator 8.
- Known hypersensitivity to study drug or any of its ingredients.
- Pregnancy and lactation 10.
- Any Malignancy 11.
- History of alcohol and drug abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of the study drug will be assessed on the basis Sore throat questionnaire At baseline, 14th day and 21 day of treatment.
- Secondary Outcome Measures
Name Time Method Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination. At baseline and after 14days
Trial Locations
- Locations (2)
Clinical Research Unit
🇮🇳Kannur, KERALA, India
Regional Institute of Unani Medicine
🇮🇳Delhi, DELHI, India
Clinical Research Unit🇮🇳Kannur, KERALA, IndiaDr MAWAHEEDPrincipal investigator7356589599mawaheed313@gmail.com